Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference
Half of ovarian cancer patients in a small study responded to a combination of Tesaro's Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 Meeting in Madrid. It was one of a host of presentations the company delivered on Zejula (niraparib) and another of its ovarian cancer therapies, TSR-042. The conference ran from Sept. 8-12. Among the highlights were trials exploring combinations of Zejula — approved in the U.S. in March 2017 as a maintenance therapy for women with ovarian cancer — and cancer immunotherapy drugs. Another intriguing presentation was a study suggesting that watchful waiting after a chemotherapy round for ovarian cancer is a bad treatment approach. “Zejula is the market-leading PARP inhibitor, with unsurpassed efficacy in a broad patient population and convenient, once-daily dosing,” Mary Lynne Hedley, president and chief operating officer of Tesaro, said in a press release. The drug was the focus of no fewer than six presentations. Several reported data from the Phase 3 NOVA trial (NCT01847274) in which women who had completed chemotherapy received Zejula as a maintenance therapy. The trial showed that many patients experience residual symptoms after chemotherapy. Zejula did not improve patient-reported outcomes or quality of life, the trial indicated. It did show that the drug is equally
Subscribe or to access all post and page content.